Toll-like receptors in esophageal cancer

Frontiers in Immunology

Volumn 5, Issue MAY, 2014, Pages

  Kauppila, Joonas H ^a,b,c   Selander, Katri S ^d,e  

^a UNIVERSITY OF OULU   (Finland)

^b MEDICAL RESEARCH CENTER OULU   (Finland)

^c OULU UNIVERSITY HOSPITAL   (Finland)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e LAPLAND CENTRAL HOSPITAL   (Finland)

Author keywords

Esophageal adenocarcinoma; Esophageal cancer; Esophageal squamous cell carcinoma; Microbiome; Toll like receptors

Indexed keywords

INTERLEUKIN 8; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 7;

BARRETT ESOPHAGUS; CANCER PROGNOSIS; EPITHELIUM CELL; ESOPHAGUS CANCER; GASTROESOPHAGEAL REFLUX; HUMAN; INFLAMMATION; INNATE IMMUNITY; PROTEIN EXPRESSION; SHORT SURVEY; SQUAMOUS CELL CARCINOMA;

EID: 84905440790     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00200     Document Type: Short Survey

References (44)

1. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol (2003) 21:335-76. doi: 10.1146/annurev.immunol.21.120601.141126
2. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol (2004) 4(7):499-511. doi:10.1038/nri1391
3. Li M, Zhou Y, Feng G, Su SB. The critical role of Toll-like receptor signaling pathways in the induction and progression of autoimmune diseases. Curr Mol Med (2009) 9(3):365-74. doi:10.2174/156652409787847137
4. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin (2005) 55(2):74-108. doi:10.3322/canjclin.55.2.74
5. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 127(12):2893-917. doi:10.1002/ijc.25516
6. Pickens A, Orringer MB. Geographical distribution and racial disparity in esophageal cancer. Ann Thorac Surg (2003) 76(4):S1367-9. doi:10.1016/S0003-4975(03)01202-5
7. Garavello W, Negri E, Talamini R, Levi F, Zambon P, Dal Maso L, et al. Family history of cancer, its combination with smoking and drinking, and risk of squamous cell carcinoma of the esophagus. Cancer Epidemiol Biomarkers Prev (2005) 14(6):1390-3. doi:10.1158/1055-9965.EPI-04-0911
8. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol (2006) 24(14):2137-50. doi:10.1200/JCO.2005.05.2308
9. Rautemaa R, Hietanen J, Niissalo S, Pirinen S, Perheentupa J. Oral and oesophageal squamous cell carcinoma - a complication or component of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED, APS-I). Oral Oncol (2007) 43(6):607-13. doi:10.1016/j.oraloncology.2006.07.005
10. Kamangar F, Chow WH, Abnet CC, Dawsey SM. Environmental causes of esophageal cancer. Gastroenterol Clin North Am (2009) 38(1):27-57,vii. doi:10.1016/j.gtc.2009.01.004
11. Fitzgerald RC. Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma. Gut (2006) 55(12):1810-20. doi:10.1136/gut.2005.089144
12. Sikkema M, de Jonge PJ, Steyerberg EW, Kuipers EJ. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol (2010) 8(3):235-44;quiz32. doi:10.1016/j.cgh.2009.10.010
13. Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med (2011) 365(15):1375-83. doi:10.1056/NEJMoa1103042
14. Jansson C, Johansson AL, Nyren O, Lagergren J. Socioeconomic factors and risk of esophageal adenocarcinoma: a nationwide Swedish case-control study. Cancer Epidemiol Biomarkers Prev (2005) 14(7):1754-61. doi:10.1158/1055-9965.EPI-05-0140
15. Corley DA, Kubo A, Levin TR, Block G, Habel L, Zhao W, et al. Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology (2007) 133(1):34-41; quiz 311. doi:10.1053/j.gastro.2007.04.046
16. Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol (2007) 17(1):2-9. doi:10.1016/j.semradonc.2006.09.003
17. Abnet CC, Freedman ND, Hollenbeck AR, Fraumeni JF Jr, Leitzmann M, Schatzkin A. A prospective study of BMI and risk of oesophageal and gastric adenocarcinoma. Eur J Cancer (2008) 44(3):465-71. doi:10.1016/j.ejca.2007.12.009
18. Corley DA, Kubo A, Zhao W. Abdominal obesity and the risk of esophageal and gastric cardia carcinomas. Cancer Epidemiol Biomarkers Prev (2008) 17(2):352-8. doi:10.1158/1055-9965.EPI-07-0748
19. Koppert LB, Wijnhoven BP, van Dekken H, Tilanus HW, Dinjens WN. The molecular biology of esophageal adenocarcinoma. J Surg Oncol (2005) 92(3):169-90. doi:10.1002/jso.20359
20. Cai YC, So CK, Nie AY, Song Y, Yang GY, Wang LD, et al. Characterization of genetic alteration patterns in human esophageal squamous cell carcinoma using selected microsatellite markers spanning multiple loci. Int J Oncol (2007) 30(5):1059-67. doi:10.3892/ijo.30.5.1059
21. Hulscher JB, Tijssen JG, Obertop H, van Lanschot JJ. Transthoracic versus transhiatal resection for carcinoma of the esophagus: a meta-analysis. Ann Thorac Surg (2001) 72(1):306-13. doi:10.1016/S0003-4975(00)02570-4
22. Shahbaz Sarwar CM, Luketich JD, Landreneau RJ, Abbas G. Esophageal cancer: an update. Int J Surg (2010) 8(6):417-22. doi:10.1016/j.ijsu.2010.06.011
23. Sobin LH, Gospodarowicz MK, Wittekind C, editors. International union against cancer. TNM Classification of Malignant Tumours. 7th ed. Chichester: Wiley-Blackwell (2010). 309 p.
24. Liu J, Xie X, Zhou C, Peng S, Rao D, Fu J. Which factors are associated with actual 5-year survival of oesophageal squamous cell carcinoma? Eur J Cardiothorac Surg (2012) 41(3):e7-11. doi:10.1093/ejcts/ezr240
25. Uehara A, Fujimoto Y, Fukase K, Takada H. Various human epithelial cells express functional Toll-like receptors, NOD1 and NOD2 to produce anti-microbial peptides, but not proinflammatory cytokines. Mol Immunol (2007) 44(12):3100-11. doi:10.1016/j.molimm.2007.02.007
26. Lim DM, Narasimhan S, Michaylira CZ, Wang ML. TLR3-mediated NF-{kappa}B signaling in human esophageal epithelial cells. Am J Physiol Gastrointest Liver Physiol (2009) 297(6):G1172-80. doi:10.1152/ajpgi.00065.2009
27. Lim DM, Wang ML. Toll-like receptor 3 signaling enables human esophageal epithelial cells to sense endogenous danger signals released by necrotic cells. Am J Physiol Gastrointest Liver Physiol (2011) 301(1):G91-9. doi:10.1152/ajpgi.00471.2010
28. Mulder DJ, Lobo D, Mak N, Justinich CJ. Expression of toll-like receptors 2 and 3 on esophageal epithelial cell lines and on eosinophils during esophagitis. Dig Dis Sci (2012) 57(3):630-42. doi:10.1007/s10620-011-1907-4
29. Helminen O, Huhta H, Takala H, Lehenkari PP, Saarnio J, Kauppila JH, et al. Increased Toll-like receptor 5 expression indicates esophageal columnar dysplasia. Virchows Arch (2014) 464(1):11-8. doi:10.1007/s00428-013-1505-2
30. Sheyhidin I, Nabi G, Hasim A, Zhang RP, Ainiwaer J, Ma H, et al. Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinoma. World J Gastroenterol (2011) 17(32):3745-51. doi:10.3748/wjg.v17.i32.3745
31. Takala H, Kauppila JH, Soini Y, Selander KS, Vuopala KS, Lehenkari PP, et al. Toll-like receptor 9 is a novel biomarker for esophageal squamous cell dysplasia and squamous cell carcinoma progression. J Innate Immun (2011) 3(6):631-8. doi:10.1159/000329115
32. Rousseau MC, Hsu RY, Spicer JD, McDonald B, Chan CH, Perera RM, et al. Lipopolysaccharide-induced toll-like receptor 4 signaling enhances the migratory ability of human esophageal cancer cells in a selectin-dependent manner. Surgery (2013) 154(1):69-77. doi:10.1016/j.surg.2013.03.006
33. Yang L, Francois F, Pei Z. Molecular pathways: pathogenesis and clinical implications of microbiome alteration in esophagitis and Barrett esophagus. Clin Cancer Res (2012) 18(8):2138-44. doi:10.1158/1078-0432.CCR-11-0934
34. Yang L, Lu X, Nossa CW, Francois F, Peek RM, Pei Z. Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. Gastroenterology (2009) 137(2):588-97. doi:10.1053/j.gastro.2009.04.046
35. Verbeek RE, Siersema PD, Ten Kate FJ, Fluiter K, Souza RF, Vleggaar FP, et al. Toll-like receptor 4 activation in Barrett's esophagus results in a strong increase in COX-2 expression. J Gastroenterol (2013). doi:10.1007/s00535-013-0862-6
36. Kauppila JH, Takala H, Selander KS, Lehenkari PP, Saarnio J, Karttunen TJ. Increased Toll-like receptor 9 expression indicates adverse prognosis in oesophageal adenocarcinoma. Histopathology (2011) 59(4):643-9. doi:10.1111/j.1365-2559.2011.03991.x
37. Kauppila JH, Karttunen TJ, Saarnio J, Nyberg P, Salo T, Graves DE, et al. Short DNA sequences and bacterial DNA induce esophageal, gastric, and colorectal cancer cell invasion. APMIS (2013) 121(6):511-22. doi:10.1111/apm.12016
38. Hold GL, Rabkin CS, Gammon MD, Berry SH, Smith MG, Lissowska J, et al. CD14-159C/T and TLR9-1237T/C polymorphisms are not associated with gastric cancer risk in Caucasian populations. Eur J Cancer Prev (2009) 18(2):117-9. doi:10.1097/CEJ.0b013e3283101292
39. Hold GL, Rabkin CS, Chow WH, Smith MG, Gammon MD, Risch HA, et al. A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology (2007) 132(3):905-12. doi:10.1053/j.gastro.2006.12.026
40. Chattopadhyay I, Phukan R, Singh A, Vasudevan M, Purkayastha J, Hewitt S, et al. Molecular profiling to identify molecular mechanism in esophageal cancer with familial clustering. Oncol Rep (2009) 21(5):1135-46. doi:10.3892/or_00000333
41. Kauppila JH, Mattila AE, Karttunen TJ, Salo T. Toll-like receptor 5 and the emerging role of bacteria in carcinogenesis. Oncoimmunology (2013) 2(4):e23620. doi:10.4161/onci.23620
42. Yu L, Wang L, Chen S. Endogenous toll-like receptor ligands and their biological significance. J Cell Mol Med (2010) 14(11):2592-603. doi:10.1111/j.1582-4934.2010.01127.x
43. Tuomela J, Sandholm J, Kaakinen M, Patel A, Kauppila JH, Ilvesaro J, et al. DNA from dead cancer cells induces TLR9-mediated invasion and inflammation in living cancer cells. Breast Cancer Res Treat (2013) 142(3):477-87. doi:10.1007/s10549-013-2762-0
44. Ding L, Lu Z, Lu Q, Chen YH. The claudin family of proteins in human malignancy: a clinical perspective. Cancer Manag Res (2013) 5:367-75. doi:10.2147/CMAR.S38294